Esperion ETC 1002-043 Bempedoic Acid

Investigator: Mahendra Jain, MD

Study Coordinator:

Status: Open Not Enrolling Number: NCT02993406


Protocol Number: Pro00018397


To evaluate whether long-term treatment with bempedoic acid 180 mg/day versus placebo reduces the risk of major adverse cardiovascular events (MACE) in patients with, or at high risk for, cardiovascular disease (CVD) who are statin intolerant. This will be assessed with a composite primary efficacy endpoint that includes time to first occurrence of cardiovascular (CV) death, nonfatal myocardial infarction (MI), nonfatal stroke, hospitalization for unstable angina, or coronary revascularization
More to Explore